Text Size

In Vitro Corneal and Conjunctival Wound-Healing Assays as a Tool for Antiglaucoma Prostaglandin Formulation Characterization

Liang H., Baudouin C., Daull P., Garrigue J.-S., Brignole-Baudouin F.


  • 2022
  • Frontiers in Bioscience
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Institut de la Vision, Sorbonne Université, INSERM, CNRS, IHU Foresight, 75012 Paris, France; Quinze-Vingts National Ophthalmology Hospital, IHU Foresight, 75012 Paris, France; University of Versailles Saint Quentin en Yvelines, 78000 Versailles, France; Santen SAS, 91000 Evry, France; Toxicology Department, Faculty of Pharmaceutical and Biological Sciences, Paris Descartes University, 75006 Paris, France

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022